Riskpilot← Back to searchSign inGet full accessPerfuseCell Cronus A/S
A/SActiveCVR 31606810Nørrelundvej 10Manufacture of medical and dental instruments and supplies · NACE 3250Est. 2008— employeeswww.perfusecell.com
Revenue 2025
DKK 20K
-97% vs 2024
EBITDA margin
100.0%
+136547% vs 2024
Equity ratio
46.9%
Financial strength
Net profit 2025
DKK 24K
+982% vs 2024
| Revenue | DKK 20K | -97% |
| EBITDA | DKK 20K | +136547% |
| Net profit | DKK 24K | +982% |
| Total assets | DKK 2,3M | +51% |
| Equity | DKK 1,1M | +2% |
| Employees | — | — |
Legal name
PerfuseCell Cronus A/S
CVR number
31606810
Legal form
Aktieselskab
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
1. juli 2008
Share capital
DKK 500.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen.
Company purpose
Selskabets formål er at drive industriel forsknings- og fremstillingsvirksomhed samt handel med udstyr til den farmaceutiske branche og hermed forbunden virksomhed.
Address
Nørrelundvej 10
Phone
+4544115400
Email
info@perfusecell.com
Website
www.perfusecell.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -45 | 3 | 0 | 0 | 0 | 1.748 | 532 | 220 | 385 | 150 | 550 | 711 | 625 | 20 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -45 | -1 | -3 | -0 | 0 | 309 | 168 | 172 | 87 | 34 | 131 | 150 | -0 | 20 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -45 | -1 | -3 | -0 | 0 | 309 | 168 | 172 | 87 | 34 | 131 | 150 | -0 | 20 |
| Net financials | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 22 | 2 | 4 |
| Profit before tax | -45 | -1 | -3 | -0 | 0 | 309 | 168 | 172 | 87 | 34 | 152 | 171 | 2 | 24 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 63 | -0 | -0 | 0 |
| Net profit | -45 | -1 | -3 | -0 | 0 | 309 | 168 | 172 | 87 | 34 | 89 | 171 | 2 | 24 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 22 | 17 | 15 | 14 | 14 | 690 | 581 | 663 | 750 | 784 | 873 | 1.045 | 1.516 | 2.283 |
| Equity | 18 | 17 | 15 | 14 | 14 | 323 | 491 | 663 | 750 | 784 | 873 | 1.045 | 1.047 | 1.071 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 | 0 | 0 | 0 | 0 | 367 | 91 | 0 | 0 | 0 | 0 | 0 | 469 | 1.212 |
| Total debt | 4 | 0 | 0 | 0 | 0 | 367 | 91 | 0 | 0 | 0 | 0 | 0 | 469 | 1.212 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20122025
Equity ratio
46.9%
This company
38.2%
Market median
+23% vs market
20122025
Return on equity
2.2%
This company
18.4%
Market median
-88% vs market
20122025
Net profit margin
117.1%
This company
8.1%
Market median
+1346% vs market
20122025
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20122025
Debt / equity
1.13×
This company
0.62×
Market median
-82% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PS Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
NJ Management | Management | 2008 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2008 | — | — | |
| Board of Directors | 2008 | — | — | |
| Board of Directors | 2026 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PerfuseCell Cronus A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Stobbe | Chief Executive Officer | 0 companies |
| Niels Johansen | Management | 0 companies |
| Flemming Petersen | Board of Directors | 0 companies |
| Erik Johansen | Board of Directors | 0 companies |
| August Kisling Stobbe | Board of Directors | 0 companies |